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Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral psychiatric disorder that
afflicts children, with a reported prevalence of 2.4% to 19.8% worldwide. Stimulants (methylphenidate [MPH] and
amphetamine) are considered first-line ADHD pharmacotherapy. MPH is a catecholamine reuptake inhibitor, whereas
amphetamines have additional presynaptic activity. Although MPH and amphetamine can effectively manage ADHD
symptoms in most pediatric patients, many still fail to respond optimally to either. After administration, the prodrug
stimulant lisdexamfetamine dimesylate (LDX) is converted to l-lysine and therapeutically active d-amphetamine in the
blood. The objective of this study was to evaluate the clinical efficacy of LDX in children with ADHD who remained
symptomatic (ie, nonremitters; ADHD Rating Scale IV [ADHD-RS-IV] total score > 18) on MPH therapy prior to
enrollment in a 4-week placebo-controlled LDX trial, compared with the overall population.
Methods: In this post hoc analysis of data from a multicenter, randomized, double-blind, forced-dose titration
study, we evaluated the clinical efficacy of LDX in children aged 6-12 years with and without prior MPH treatment
at screening. ADHD symptoms were assessed using the ADHD-RS-IV scale, Conners’ Parent Rating Scale-Revised
short form (CPRS-R), and Clinical Global Impressions-Improvement scale, at screening, baseline, and endpoint.
ADHD-RS-IV total and CPRS-R ADHD Index scores were summarized as mean (SD). Clinical response for the
subgroup analysis was defined as a ≥ 30% reduction from baseline in ADHD-RS-IV score and a CGI-I score of 1 or
2. Dunnett test was used to compare change from baseline in all groups. Number needed to treat to achieve one
clinical responder or one symptomatic remitter was calculated as the reciprocal of the difference in their
proportions on active treatment and placebo at endpoint.
Results: Of 290 randomized participants enrolled, 28 received MPH therapy at screening, of which 26 remained
symptomatic (ADHD-RS-IV > 18). ADHD-RS-IV total scores, changes from baseline, clinical responsiveness, and rates
of symptomatic remission in this subgroup were comparable to the overall population. The safety and tolerability
profiles for LDX were comparable to other stimulants currently available.
Conclusion: In this analysis, children with significant clinical ADHD symptoms despite MPH treatment improved
during treatment with LDX and experienced similar improvements in their symptoms as the overall study population.
Trial Registration: ClinicalTrials.gov: NCT00556296
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Attention-deficit/hyperactivity disorder (ADHD) is one
of the most common neurobehavioral psychiatric disor-
ders that afflicts children [1], with a reported prevalence
of 2.4% to 19.8% worldwide [2] using the criteria from
the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition (DSM-IV) from the American Psy-
chiatric Association [3]. Two Canadian studies of
children and adolescents, using earlier diagnostic criteria
to examine ADHD prevalence, estimated a prevalence of
6.3% in an Ontario study of participants (aged 4 to 16
years) [4], and 3.3% to 8.9% in a comparable population
(aged 6 to 14 years) in Quebec [5].
Stimulants have long been used to treat ADHD symp-
toms. The Texas Consensus Conference Panel on Phar-
macotherapy of Childhood ADHD algorithm [6]
considered psychostimulants as first-line pharmacother-
apy treatments for ADHD; However, the Canadian
ADHD Resource Alliance (CADDRA) guidelines con-
sider long-acting stimulants and atomoxetine as first-
line agents in the management of ADHD [7]. The sti-
mulant types most commonly used in ADHD treatment
are methylphenidate (MPH) and amphetamine. These
have similar subjective effects [8] yet differ in their
mechanisms of action–MPH is a dopamine and norepi-
nephrine reuptake inhibitor, while amphetamines have
additional presynaptic activity–stimulating the release of
dopamine, norepinephrine, and serotonin [9]. Although
both are considered efficacious, a meta-analysis of 23
studies comparing the efficacy of immediate-release (IR)
formulations of MPH and amphetamine in the treat-
ment of children with ADHD revealed small but statisti-
cally significant differences in favor of amphetamine
[10]. A comparative review of controlled crossover stu-
dies [11] found that clinical response rates for IR formu-
lations of MPH and amphetamine ranged from 57% to
68% and 69% to 77%, respectively. The review also esti-
mated that 87% to 92% participants respond to at least
one of these stimulants. However, although MPH and
amphetamine can effectively manage ADHD symptoms
in most pediatric patients, many patients still fail to
respond optimally to either.
Lisdexamfetamine dimesylate (LDX; Vyvanse
®)i sa
prodrug stimulant with a novel delivery mechanism,
approved in Canada [12] and the United States [13] for
the treatment of ADHD in children 6 to 12 years of age,
adolescents aged 13 to 17 years, and adults. LDX is a
therapeutically inactive molecule. LDX is converted, pri-
marily in the blood, to l-lysine and therapeutically active
d-amphetamine [14]. In Canada, the approved dosages
range from 20 to 60 mg capsules for once daily oral
administration and in the United States from 20 to 70
mg also once daily [12,13].
LDX has been shown to be effective from 1.5 to 13
hours postdose in children [15], and from 2 to 14 hours
postdose in adults [16]. In a randomized controlled trial
(RCT), LDX was associated with improvements in clinical
symptoms of ADHD in children while maintaining a
safety profile similar to other stimulant medications [17].
In this post hoc analysis from the RCT, the efficacy of
LDX in a subset of children, who had significant ADHD
symptoms at study enrollment despite receiving MPH
treatment, was evaluated to determine clinical response
to LDX therapy in these study participants. Based on
previous findings that some patients fail to achieve opti-
mal response to either MPH or amphetamine, children
who were previously treated with MPH and continue to
have ADHD symptoms may be responsive to ampheta-
mine-based ADHD treatment.
Methods
The methods used in this study for the overall study
population have been described previously [17]. This
was a multicenter, randomized, double-blind, forced-
dose titration, parallel-group study, conducted in accor-
dance with the Guideline for Good Clinical Practice
from the World Health Organization and the Declara-
tion of Helsinki and its amendments.
Participants
Biederman et al previously described full inclusion/exclu-
sion criteria [17]. Briefly, children aged 6 to 12 years who
met DSM-IV-TR criteria for a primary diagnosis of
ADHD [18] and had a ADHD Rating Scale IV (ADHD-
RS-IV) [19,20] score of ≥ 28 at baseline after washout
were eligible for inclusion, regardless of medication used
for ADHD at screening.
Study Design
The study comprised a 1-week screening period; a 1-
week washout period of prior psychoactive medications;
and 4-weeks of double-blind treatment. During screening,
participants received an initial ADHD-RS-IV evaluation.
Participants receiving medication for ADHD at enroll-
ment were allowed to continue their medication during
the screening evaluation. After screening, the parents/
caregivers of eligible participants were instructed to dis-
continue their prior ADHD medications, if they had not
already done so.
Baseline assessments were made after the 1-week wash-
out. Participants were randomized in a 1:1:1:1 ratio (using
a block-randomization schedule) to receive double-blind,
oral administration of LDX 30 mg/day for 4 weeks, 50
mg/day (30 mg/day for week 1, 50 mg/day for weeks 2 to
4), 70 mg/day (30 mg/day for week 1, 50 mg/day for week
2 ,7 0m g / d a yf o rw e e k s3a n d4 ) ,o rp l a c e b of o r4w e e k s .
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The primary efficacy outcome was the change in mean
ADHD-RS-IV total score from baseline to treatment
endpoint, defined as the last postrandomization week
for which a score was obtained. ADHD-RS-IV total
score assessments were based on investigator interviews
with the caregiver and child regarding symptom severity
during the preceding week.
Secondary efficacy measures included ADHD-RS-IV
total scores at screening, baseline, and endpoint; percent
change in ADHD-RS-IV total score; the Conners’ Parent
Rating Scale-Revised (CPRS-R: Short Form) [21]; and the
investigator-rated Clinical Global Impressions (CGI) scale
[22]. The CGI-Severity (CGI-S) assessment was con-
ducted at the baseline visit and the CGI-Improvement
(CGI-I) assessment was conducted at subsequent visits.
Efficacy was assessed in the overall efficacy population,
all participants who had ADHD-RS-IV scores recorded
at baseline and at least one other postrandomization
time point.
Post Hoc Efficacy Analyses
This post hoc efficacy analysis assessed treatment effects
of LDX and placebo in participants receiving MPH prior
to entering the present study, who had available screen-
ing data and significant ADHD symptoms prior to dis-
continuing their MPH regimen. Efficacy was further
evaluated according to mean daily MPH dose received
(≥ 1 mg/kg vs < 1 mg/kg) during prior treatment.
Rates of symptomatic remission and clinical response
were evaluated throughout the study in participants
receiving prior MPH therapy and the efficacy population.
Steele et al [23] suggested that treatment response be
considered as an improvement in symptom scores from
baseline of 25% to 30%. However, reductions from base-
line do not take into account potential differences in
baseline severity of disease. Participants with severe
symptoms at baseline may be considered responders but
still exhibit symptoms. Hence, a clinical response defini-
tion that includes a percent reduction in symptoms and
a measure of global clinical improvement, such as the
CGI-I, may be a better measure of clinical response to
treatment. Moreover, other studies have shown that a 1-
level change on the CGI-I was consistent with an esti-
mated 10- to 15-point or 25% to 30% change from base-
line in ADHD-RS-IV total score [24].
In the primary analysis [17], Biederman et al reported on
the ADHD-RS-IV (primary outcome measure) and CGI-I
(secondary outcome measure) as continuous measures. In
this present analysis, clinical response to LDX treatment
was defined as a dual criteria of ≥ 30% reduction in
ADHD-RS-IV total score from baseline and a CGI-I score
of 1 or 2 at endpoint based on data from previous reports
defining response [23,25]; symptomatic remission was
defined as ADHD-RS-IV total score of ≤ 18 [26]. Conver-
sely, nonremitters on prior MPH were defined as partici-
pants with an ADHD-RS-IV total score > 18 while
receiving MPH prior to entering the study. Number-
needed-to-treat (NNT) for 1 participant to achieve a ther-
apeutic clinical response or symptomatic remission at
treatment endpoint was calculated to translate the efficacy
data into more clinically meaningful terms.
Safety Assessments
Safety assessments, in enrolled participants who received
at least 1 dose of study medication, have been reported
previously [17]. Briefly, these included adverse events
(AEs), electrocardiograms (ECGs), blood pressure (BP),
heart rate, and laboratory assessments. Treatment-emer-
gent AEs (TEAEs) were coded using the Medical Dic-
tionary for Regulatory Activities version 7.1 [27]. TEAEs
referred to events with onset after the first date of treat-
ment and no later than 3 days following termination of
treatment. No separate assessments were performed in
nonremitters on prior MPH due to low sample numbers
and no reason to expect differences in safety/tolerability
in these participants.
Statistical Analyses
ADHD-RS-IV total and CPRS-R ADHD Index scores
were summarized as mean (standard deviation [SD]).
Mean change in ADHD-RS-IV total score for the overall
population was assessed using 2-way analysis of covar-
iance. Dunnett test for multiple mean comparisons with
least-squares adjustment was used to compare change
from baseline in the 3 active treatment groups versus
placebo. NNT to achieve 1 clinical responder or 1 symp-
tomatic remitter was calculated as the reciprocal of the
difference in proportions of clinical responders or symp-
tomatic remitters on active treatment and placebo at
treatment endpoint.
Results
Participant Demographics and Disposition
In total, 297 children were enrolled at 40 study sites in
the United States, of which 7 children discontinued
prior to randomization, and 290 were randomized to
receive LDX (n = 218) or placebo (n = 72). Of these,
285 had a postrandomization symptom assessment and
were included in the efficacy population. Full demo-
graphic data for this population have been previously
reported [17].
Of the 290 randomized participants, 28 were receiving
MPH treatment at screening and 26 of these were clas-
sified as nonremitters on prior MPH at the screening
visit, prior to randomization (Table 1). Median age was
9 years and 11/26 (42.3%) female and 15/26 (57.7%)
male participants were included. Prior treatment for
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Page 3 of 1019 (73.1%) participants was osmotic, controlled-release
MPH (OROS MPH), alone or in combination with
another ADHD medication (1 participant in combina-
tion with IR dex-MPH [d-MPH], 1 with IR mixed
amphetamine salts); 2 (7.7%) participants received prior
treatment with extended release (ER) MPH; 3 (7.7%)
participants received prior treatment with IR MPH; 1
(3.8%) participant was previously treated with sustained
release MPH (SR MPH); 1 (3.8%) participant was prior
treated with MPH controlled delivery (MPH CD) (Table
1). Sixteen participants (61.5%) received an average daily
dose of ≥ 1 mg/kg MPH, and 10 (38.5%) an average
daily dose of < 1 mg/kg MPH.
Changes in ADHD-RS-IV Total Scores
Mean (SD) screening, baseline, and endpoint ADHD-RS-
IV total scores for nonremitters during prior MPH
treatment, nonremitters stratified according to prior
MPH dosage received, and overall efficacy population
are shown in Figure 1.
T h em e a n( S D )c h a n g ei nA D H D - R S - I Vt o t a ls c o r e
from baseline with LDX treatment was -24.0 (12.56)
(Figure 2), corresponding to a mean (SD) percentage
reduction of 57 (29.9%) in the 19 nonremitters on prior
MPH treatment. The mean (95% confidence interval
[CI]) placebo-adjusted ADHD-RS-IV total score reduc-
tion for this group was -17.6 (-29.65, -5.49; P = .0063).
Table 1 Baseline Demographic and Clinical Characteristics of Randomized Participants Classified as Nonremitters
During Prior MPH Treatment
Participant Age (years) Sex Weight (kg) Medication Total Daily Dose
(mg/day)
Average Daily Dose
(mg/kg)
Screening ADHD-RS-IV
Total Score
1 6 F 22.68 OROS MPH* ≥ 30 ≥ 1.0 50
2 7 M 29.48 ER MPH 20 < 1.0 20
3 7 F 44.45 OROS MPH 36 < 1.0 28
4 8 M 44.36 OROS MPH 18 < 1.0 38
5 8 M 26.31 OROS MPH 54 ≥ 1.0 38
6 8 M 33.57 OROS MPH;
IR dMPH
54;
2.5
≥ 1.0 50
7 8 M 41.28 OROS MPH 18 < 1.0 43
8 8 F 43.68 IR MPH 30 < 1.0 50
9 9 M 29.03 ER MPH 20 < 1.0 29
10 9 M 26.76 OROS MPH 54 ≥ 1.0 39
11 9 M 31.75 MPH CD 40 ≥ 1.0 29
12 9 M 26.31 OROS MPH 27 ≥ 1.0 45
13 9 F 28.12 SR MPH 20 < 1.0 40
14 9 F 25.18 IR MPH* ≥ 50 ≥ 1.0 34
15 9 F 24.90 OROS MPH 27 ≥ 1.0 20
16 10 M 39.01 OROS MPH 54 ≥ 1.0 23
17 10 F 43.68 OROS MPH
† 36 < 1.0 22
18 10 F 27.67 OROS MPH 54 ≥ 1.0 37
19 10 F 29.03 IR MPH 50 ≥ 1.0 44
20 11 M 45.36 OROS MPH 72 ≥ 1.0 35
21 11 M 45.36 OROS MPH 36 < 1.0 41
22 12 M 39.46 OROS MPH 54 ≥ 1.0 45
23 12 M 34.02 OROS MPH 18 < 1.0 45
24 12 M 33.57 OROS MPH 54 ≥ 1.0 44
25 12 F 34.02 OROS MPH 36 ≥ 1.0 51
26 12 F 26.76 OROS MPH 54 ≥ 1.0 25
ADHD-RS-IV = Attention-Deficit/Hyperactivity Disorder Rating Scale IV; dMPH = dexmethylphenidate; ER = extended-release; IR = immediate-release; MPH =
methylphenidate; CD = controlled delivery; OROS = osmotic-release oral system; SR = sustained-release.
*Exact dose of treatment for these participants could not be determined;
†Participant was also receiving 40 mg/d of IR mixed amphetamine salts although this
was not included in the calculation of MPH dose.
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Responders
Of the 26 nonremitters on prior MPH at screening, 12
(63.2%) participants receiving LDX and 1 (14.3%) receiv-
ing placebo were classified as remitters during the study
(Figure 3). Similar patterns of symptomatic remission
with LDX treatment were observed in the overall effi-
cacy population. As well, patterns of symptomatic
remission were similar with placebo treatment in the
overall efficacy population and in nonremitters on prior
MPH. The NNT (95% CI) to achieve symptomatic
remission with LDX at treatment endpoint was 2.0
(1.21, 6.63) in nonremitters and 2.1 (1.74, 2.72) in the
overall study population.
Of nonremitters on prior MPH, clinical response was
achieved in 15 (78.9%) treated with LDX and 3 (42.9%)
treated with placebo, respectively. In the overall efficacy
population, 169 (79.3%) treated with LDX and 21
(29.2%) treated with placebo achieved clinical response
(Figure 4). Of the 169 LDX clinical responders, 54
(32.0%) received 30 mg/d LDX, 55 (32.5%) received 50
m g / dL D X ,a n d6 0( 3 5 . 5 % )r e c e i v e d7 0m g / dL D X .
NNT (95% CI) to achieve clinical response with LDX at
treatment endpoint was 2.0 (1.21, 6.63) in nonremitters
on prior MPH, versus 1.8 (1.51, 2.22) in the overall
population.
Changes in CPRS-R ADHD Index Scores
Mean (SD) morning, afternoon, and evening CPRS-R
ADHD index scores at baseline and endpoint in nonre-
mitters on prior MPH are shown in Figure 5. The mean
changes from baseline morning, afternoon, and evening
CPRS-R ADHD index scores were -14.7 (10.90), -12.2
(12.89), and -13.4 (11.69) for the LDX groups, respec-
tively, and -1.3 (14.92), -0.1 (9.01), and 0.4 (11.25) for
the placebo group, respectively. These data were similar
to the CPRS-R ADHD index scores observed in the
overall population [17].
Safety and Tolerability
Full safety analyses have been reported previously [17].
In the safety population, 196/290 (68%) participants
reported one or more TEAEs; 21/290 (7.2%) discontin-
ued due to TEAE. TEAEs with an incidence ≥ 5% in the
combined LDX group were decreased appetite, insom-
nia, headache, upper abdominal pain, irritability, weight
loss, vomiting, nausea, dizziness, and nasopharyngitis
and, in the placebo group, were headache, cough, nasal
congestion, nasopharyngitis, and upper abdominal pain.
No serious AEs were observed during the study. More
than 95% of TEAEs were mild or moderate in intensity
and most began during the first week of treatment and
abated over time [17]. Mean (SE) change from baseline
at endpoint for pulse (bpm) ranged from 0.3 (1.20) to
4.1 (1.17) in all LDX groups and was -0.7 (1.17) in the
placebo group. The systolic BP change for all LDX
groups ranged from 0.4 (1.08) to 2.6 (1.05) mm Hg and
for placebo was 1.3 (1.05) mm Hg. For diastolic BP the
change ranged from 0.6 (0.93) to 2.3 (0.91) mm Hg for
all LDX groups and was 0.6 (0.91) mm Hg for the pla-
cebo group. LDX treatment was not associated with any
significant changes in mean BP, ECG parameters, and
laboratory values.
Discussion
In this post hoc analysis, LDX showed efficacy when
given to children with significant clinical ADHD symp-
toms despite prior MPH treatment. Efficacy outcomes
were similar to the results of the overall population
assessed in the clinical trial.
Among participants previously treated with MPH,
more than half were receiving doses (average daily dose
≥ 1 mg/kg) considered generally effective according to
the regimens administered in randomized, controlled
trials [28,29]. Conversely, just under half may have
received suboptimal doses. Moreover, none of these
measures differed from those observed in the overall
study population. Although this study was not powered
to detect differences between the treatment groups, the
percentage of clinical responders in the overall study
group was comparable regardless of LDX dose received.
Similarly, no apparent differences occurred between the
NNTs to achieve clinical response or symptomatic
remission for the overall efficacy population and nonre-
mitters on prior MPH. The NNT values calculated are
comparable or superior to those reported elsewhere in
the literature for symptomatic remission and clinical
response to MPH and atomoxetine, which range from
approximately 1.9 to 5.3 depending on formulation and
types of raters [30].
Differential responses to MPH and amphetamine may
explain a successful clinical response to LDX in partici-
pants who had significant ADHD symptoms despite
prior MPH therapy. In 2 separate crossover studies
[31,32] comparing the efficacy of MPH and dextroam-
phetamine, most children with ADHD who did not
respond to 1 stimulant responded to the other. A bimo-
dal pattern of clinical response to atomoxetine has been
described, with no obvious demographic or clinical pre-
dictors of clinical response [33].
Clinical trial design may have contributed to the
observed clinical response to LDX treatment in nonre-
mitters on prior MPH. LDX treatment was administered
in a forced-dose titration, while prior MPH therapy was
provided according to community standards and
included potential suboptimal dosing. Use of different
definitions of therapeutic response may have altered the
rates observed.
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tion of participants as nonremitters on prior MPH con-
siders only the ADHD-RS-IV total score at screening
and may not reflect the participants’ overall clinical
response to MPH. It should be noted that switching
from MPH formulations to LDX was done as part of
the study protocol and not purely as a clinical practice
decision.
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polate the findings to the long-term treatment generally
required in managing ADHD. This study was not pro-
spectively designed or powered to detect differences
between the treatment groups. A prospective study
would be required to confirm these preliminary findings.
Conclusions
In this post hoc analysis of children who had significant
clinical ADHD symptoms despite previous MPH treat-
ment, LDX demonstrated efficacy and clinical response
in the subpopulation assessed. Efficacy outcomes in this
population were similar to those in the overall study
population.
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